NCT05048875: An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge |
|
|
| Recruiting | 2 | 54 | US | JNJ-64281802 (sentinel high dose), JNJ-64281802 (remaining high dose), JNJ-64281802 (medium/low dose), JNJ-64281802 (daily dosing regimen X), JNJ-64281802 (weekly dosing regimen Y1), JNJ-64281802 (weekly dosing regimen Z2), Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Janssen, LP, National Institutes of Health (NIH) | Dengue | 05/23 | 08/24 | | |
| Recruiting | 2 | 84 | US | AV-1 100 mg, AV-1 300 mg, AV-1 900 mg, Placebo | AbViro LLC | DENV-3 Controlled Human Infection Model | 10/25 | 10/25 | | |